
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen has demonstrated robust financial performance, with total orders increasing by 11% year-over-year in 4Q24, showcasing strong demand across its product categories, particularly in chromatography and capital equipment. The company achieved a notable revenue growth projection of 9.9% for 2025, supported by significant gains in CDMO and equipment sales, which exhibited sequential revenue increases of 20% and 30% respectively. Furthermore, Repligen successfully expanded its adjusted gross margin by 140 basis points in 2024 while implementing effective cost controls, positioning itself for sustained profitability and operational efficiency.
Bears say
Repligen faces a negative outlook due to several fundamental challenges impacting its financial performance, including a slowdown in purchasing from small biotech companies, which threatens revenue stability within a key customer segment. The company has experienced eroded visibility regarding customer inventory levels and spending plans, leading to a reduced order book and the subsequent downgrading of revenue expectations twice in 2024. Additionally, the transition of the well-regarded CEO Tony Hunt to Executive Chair introduces uncertainty, further exacerbating concerns over potential revenue slowdowns and fluctuations in the company's trading multiples.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares